September 20, 2020 10:20 AM EDTUpdated 12:35 PM
R&D

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

John Carroll

Editor & Founder

Any $12 bil­lion megablock­buster in the port­fo­lio tends to over­shad­ow every­thing else in the pipeline. Which is some­thing Mer­ck can tell you a lit­tle bit …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease med­i­cine: ‘We need to sit down with Elon Musk’

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Pfiz­er vet William Pao’s next ven­ture; Sanofi’s com­pu­ta­tion­al sci­ence ex­ec leaves

Can Bill An­der­son save Bay­er?

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times